Info

🌱 來自：Second-line or maintainence therapy for idiopathic thrombocytopenic purpura

TPO-R agonists

• having an overall response rate of ∼75%
• a durable response rate (response at 6 months) of ∼65%

Drugs

• Romiplostim

  • Route of administration: Subcutaneous injections
  • Mechanism of action: TPO-RA
  • Dosage: 1-10 µg/kg once weekly
  • Response rate: Overall response of 75%; durable response at 6 months is 65%; 10% to 30% may achieve treatment remission
  • Adverse effects:
    • Headache
    • Muscle aches
    • Venous and arterial thromboembolism
    • Possible increase in bone marrow reticulin and collagen fibrosis

• Eltrombopag

  • Route of administration: Oral (restricted diet)
  • Mechanism of action: TPO-RA
  • Dosage: 25-75 mg once daily
  • Response rate: Not specified
  • Adverse effects:
    • Headache
    • Venous and arterial thromboembolism
    • Elevated liver enzymes
    • Possible increase in bone marrow reticulin and collagen fibrosis

• Avatrombopag

  • Route of administration: Oral
  • Mechanism of action: TPO-RA
  • Dosage: 20-40 mg once daily
  • Response rate: 65% at day 8*
  • Adverse effects:
    • Headaches
    • Arthralgia
    • Venous and arterial thromboembolism